Abstract
The current neuropathological staging models of Alzheimer’s disease (AD) have been developed within the last 20 years. Nevertheless, they were mostly tested on Caucasians of Northern European ancestry or on Asians.ObjectiveTo verify which of the accepted neuropathologic criteria best discriminates AD from normal aging in a well characterized Brazilian clinicopathological series.MethodsA random sample consisting of 89 subjects belonging to the Brazilian Brain Bank of the Aging Brain Study were clinically and neuropathologically fully assessed using immunohistochemistry. Clinical and functional statuses were assessed by interviewing a reliable informant. The Clinical dementia rating scale (CDR) was compared to Braak and Braak stage, the consortium to establish a registry for Alzheimer’s disease (CERAD) score and NIA-Reagan (National Institute of Aging - Reagan Institute) score. Subjects with a neuropathologic diagnosis other then AD were excluded (n=27).ResultsThe CDR score distribution for the 62 selected subjects was as follows: CDR0=39, CDR0.5=9, CDR1=14. There were no differences regarding age, gender and education among the groups. CDR score correlated best with the CERAD score (r=0.5303; p<0.001) . Braak and Braak stage was significantly higher in subjects with higher CDR. Correlation of the NIA-Reagan criteria was partially disrupted because a large proportion of subjects did not fit any of its categories.ConclusionsIn this series, CERAD criteria better correlated with the CDR groups. Consistent with earlier studies, some cognitively normal subjects have AD neuropathological diagnosis.
Highlights
The current neuropathological staging models of Alzheimer’s disease (AD) have been developed within the last 20 years
While the relationship of the maximum frequency of neuritic plaques (NP) with the age of the subject associated to the history of dementia are the pivotal constituents of the Consortium to Establish a Registry for Alzheimer’s Disease criteria (CERAD),[2] the distribution and burden of neurofibrillary tangles (NFT) determine each of the seven Braak and Braak stages.[3]
The purpose of this study was to examine which of the accepted neuropathologic criteria best discriminate AD from clinical normal aging in a clinicopathological series of 89 subjects belonging to the Brazilian Brain Bank of the Aging Brain Study Group (BBBABSG)
Summary
Abstract – The current neuropathological staging models of Alzheimer’s disease (AD) have been developed within the last 20 years. The Clinical dementia rating scale (CDR) was compared to Braak and Braak stage, the consortium to establish a registry for Alzheimer’s disease (CERAD) score and NIA-Reagan (National Institute of Aging - Reagan Institute) score. Os escores na Clinical Dementia Rating Scale (CDR) foram comparados com os escores dos estágios de Braak e Braak, do CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) e do consórcio NIA-Reagan (National Institute of Aging-Reagan Institute). The purpose of this study was to examine which of the accepted neuropathologic criteria best discriminate AD from clinical normal aging in a clinicopathological series of 89 subjects belonging to the Brazilian Brain Bank of the Aging Brain Study Group (BBBABSG)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
